Clinical trials: Liver Diseases, Alcoholic
Fatty Liver Disease, Fatty Liver
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
- Trial name
- MAFLD (NCT05966025)
- Testing
- Itopride, conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
NAFLD, Non Alcoholic Steatohepatitis (NASH)
DHA and Vitamin D in Children With Biopsy-proven NAFLD
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Trial name
- VitD_DHA (NCT02098317)
- Testing
- DHA plus Vitamin D
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity
Non-Invasive Diagnostic Panel for MASLD in Children With Obesity
This prospective, single-center, two-group observational study evaluates a non-invasive multi-parameter diagnostic panel for metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Insulin Resistance Syndrome
- Trial name
- PedMASLD-Pilot (NCT07731360)
- Testing
- Non-Invasive Multi-Parameter Diagnostic Panel
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people
- Sponsor
- Kayseri City Hospital
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT03248882
- Testing
- PF-05221304
- Where
- 140 sites in United States, Australia and 4 more
- Volunteers
- 305 people
- Sponsor
- Pfizer
MASH, NASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression…
- Conditions
- MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis
- Trial name
- FASCINATE-3 (NCT06594523)
- Testing
- Denifanstat
- Sponsor
- Sagimet Biosciences Inc.
Non Alcoholic Fatty Liver Disease
The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver
The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01956825
- Testing
- "slim water"
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Meir Medical Center
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Obesity, NAFLD
Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
The aim of the study is to estimate the effectiveness of two different exercise programs combined with the Mediterranean diet versus diet alone on inflammatory status in subjects aged 18-65 years with obesity (BMI>30) and…
- Trial name
- Obesity_AF (NCT06186869)
- Testing
- Aerobic Exercise and diet intervention, Hiit and diet intervention, Diet
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Diabetes Mellitus Type 2, Dyslipidemia
Low Calorie Diet and Diabetes
The primary hypothesis is to investigate whether a low calorie diet for 7 weeks followed by continuous lifestyle advice is an effective option to achieve an improvement in glucose control as measured by HbA1c after 52 and 104…
- Conditions
- Diabetes Mellitus Type 2, Dyslipidemia, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- LCD (NCT02498990)
- Testing
- Low calorie diet followed by life style intervention
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
This study will evaluate the association of non-alcoholic fatty liver disease and diabetes mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive the following examination: Transient…
- Trial name
- NCT01997424
- Testing
- Controlled Attenuation Parameter (CAP), Echosens, Paris, France, FibroScan, Echosens, Paris, France
- Where
- Germany
- Volunteers
- 340 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Non-Alcoholic Steatohepatitis (NASH)
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04140123
- Testing
- ZSP1601
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Obesity, Non-Alcoholic Fatty Liver Disease
Evaluation of Intestinal Microbiome in Obese Kids
The goal of this study is to investigate comparisons between the intestinal microbiome in patients with obesity and in patients with obesity and Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT00816296
- Testing
- Blood Draw, Stool collection, BodPod Measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Nonalcoholic Steatohepatitis
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT03987074
- Testing
- Semaglutide, Firsocostat, Cilofexor
- Where
- 18 sites in United States
- Volunteers
- 109 people
- Sponsor
- Gilead Sciences
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Liver Diseases, Liver Fat
The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral
The purpose of this study is to promote the diagnosis and awareness of Non-Alcoholic Steatohepatitis (NASH) by linkage of care.
- Conditions
- Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis
- Trial name
- NCT07580482
- Testing
- Best Practice Alert, No Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Nonalcoholic Steatohepatitis (NASH)
The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis
This is a Phase 2, randomized, double-blind, placebo controlled, three arm study in adult men with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of LPCN 1144 in adult men with NASH.
- Trial name
- NASH (NCT04134091)
- Testing
- LPCN 1144 Formulation A, LPCN 1144 Formulation B
- Where
- 19 sites in United States
- Volunteers
- 56 people
- Sponsor
- Lipocine Inc.
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where fat builds up in the liver, is common in patients with type 2 diabetes.
- Trial name
- NCT07269197
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Croatia
- Volunteers
- 67 people
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Hepatitis, Alcoholic
Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).
The primary objective of this study is to determine the prevalence of AH in addition to its clinical characteristics and in-hospital mortality of patients that are hospitalized for AH in different hospitals across Latin American…
- Trial name
- NCT04142723
- Testing
- blood withdraw
- Where
- Chile
- Volunteers
- 1,000 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Fatty Liver
A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)
The purpose of this study is to evaluate the dietary supplement Siliphos, which comes from milk thistle, to determine whether it is safe and well-tolerated in adults who have non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT00443079
- Testing
- IdB 1016 (Siliphos)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Heather Patton
Non-Alcoholic Fatty Liver Disease
Liver Health and Metabolic Function in People With Obesity
This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.
- Trial name
- NCT03701828
- Testing
- Weight loss surgery
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.